A Phase 2 interventional study of bimagrumab and Placebo in Sarcopenia, sponsored by Novartis Pharmaceuticals. Completed at 30 sites in 12 countries. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2020-06-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This extension study was a 24-week off-drug follow-up of the core CBYM338E2202 (NCT ) study and the main objective was to determine the long-term durability of bimagrumab (BYM338) effect after a 6-month treatment period.
Two populations were defined as below:
1,330 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
This study's enrollment of 160 is above the median of 60 across 855 interventional studies indexed under Sarcopenia.
Browse Sarcopenia studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criterion:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo - one approximately every four weeks - over a 20-week period providing drug exposure for a total of 24 weeks.
Drug: bimagrumab · Drug: Placebo
Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.
bimagrumab low dose bimagrumab moderate dose bimagrumab high dose Patients enrolled prior to the protocol amendment 1 (Population I ), who received bimagrumab in the core study, entered the extension study at Week 25 and were randomly assigned to two subgroups within each of three treatment arms to either receive bimagrumab at the same dose level or placebo. Study medication was administered as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45.
Placebo Patients enrolled prior to the protocol amendment 1 (Population I), who received placebo in core study, entered the extension study at Week 25 and received placebo as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45.
Population I: Short Physical Performance Battery (SPPB) Total Score at Week 49
SPPB evaluates lower extremities in three functional components: maintenance of standing balance, usual gait speed and chair stand. Each test yields a score on a scale from 0 to 4 (total score 0-12, with the higher score reflecting a higher level of function).
Time frame: Week 49
Population II: Short Physical Performance Battery (SPPB) Total Score at Week 49
SPPB evaluates lower extremities in three functional components: maintenance of standing balance, usual gait speed and chair stand. Each test yields a score on a scale from 0 to 4 (total score 0-12, with the higher score reflecting a higher level of function).
Time frame: Week 49
Population I: 6-minute Walking Distance (6MWT) at Week 49
The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is able to self-pace and rest as needed as they traverse back and forth along a marked walkway. A high 6MWT represent better physical condition.
Time frame: Week 49
Population II: 6-minute Walking Distance (6MWT) at Week 49
The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is able to self-pace and rest as needed as they traverse back and forth along a marked walkway. A high 6MWT represent better physical condition.
Time frame: Week 49
Population I: Gait Speed at Week 49
Gait Speed was assessed as part of SPPB, over a 4 meter distance of a 6 meter course. Gait speed assesses a person's usual walking speed, which is defined as the speed a person normally walks from one place to another. Poor functional performance is measured by slow or declining gait speed.
Time frame: Week 49
Population II: Gait Speed at Week 49
Gait Speed was assessed as part of SPPB, over a 4 meter distance of a 6 meter course. Gait speed assesses a person's usual walking speed, which is defined as the speed a person normally walks from one place to another. Poor functional performance is measured by slow or declining gait speed.
Time frame: Week 49
Population I: Appendicular Skeletal Muscle Index (ASMI) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49
ASMI is a core requirement for determining the presence of sarcopenia and is calculated as the sum of the appendicular lean mass (kg) of the two upper and two lower limbs quantified by DXA, divided by height (m2). Therefore, an increase in ASMI indicates an increase in the quantity of an individual's lean mass.
Time frame: Week 49
Population II: Appendicular Skeletal Muscle Index (ASMI) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49
ASMI is a core requirement for determining the presence of sarcopenia and is calculated as the sum of the appendicular lean mass (kg) of the two upper and two lower limbs quantified by DXA, divided by height (m2). Therefore, an increase in ASMI indicates an increase in the quantity of an individual's lean mass.
Time frame: Week 49
Population I: Total Lean Body Mass (LBM) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49
LBM is defined as the Total soft tissue fat-free body mass. A high LBM represents better pharmacodynamic effect
Time frame: Week 49
Population II: Total Lean Body Mass (LBM) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49
LBM is defined as the Total soft tissue fat-free body mass. A high LBM represents better pharmacodynamic effect
Time frame: Week 49
This study was conducted in 30 centers in 12 countries: Australia (1), Belgium (1), Czech Republic (1), Denmark (1), France (2), Japan (10), Russia (4), South Korea (1), Spain (2), Switzerland (1), Taiwan (1), United States (5).
| Milestone | Population I: BYM338 700 mg | Population I BYM338: 700 mg to Placebo | Population I: BYM338 210 mg | Population I BYM338: 210 mg to Placebo | Population I: BYM338 70 mg | Population I: BYM338 70 mg to Placebo | Population I: Placebo | Population: II BYM338 700 mg | Population: II Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 4 | 7 | 7 | 15 | 69 | 43 |
| Completed | 4 | 5 | 5 | 3 | 6 | 6 | 14 | 65 | 40 |
| Not completed | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 4 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Patient/guardian decision | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 1 |
| Withdrew: Protocol deviation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
SPPB evaluates lower extremities in three functional components: maintenance of standing balance, usual gait speed and chair stand. Each test yields a score on a scale from 0 to 4 (total score 0-12, with the higher score reflecting a higher level of function).
| Scores on a scale | Population I: BYM338 700 mg | Population I BYM338: 700 mg to Placebo | Population I: BYM338 210 mg | Population I BYM338: 210 mg to Placebo | Population I: BYM338 70 mg | Population I: BYM338 70 mg to Placebo | Population I: Placebo |
|---|---|---|---|---|---|---|---|
| Population I: Short Physical Performance Battery (SPPB) Total Score at Week 49 | 8.8 ± 3.86 | 10.2 ± 1.92 | 8.0 ± 2.35 | 8.0 ± 2.65 | 9.5 ± 2.17 | 7.5 ± 3.78 | 9.6 ± 1.83 |
SPPB evaluates lower extremities in three functional components: maintenance of standing balance, usual gait speed and chair stand. Each test yields a score on a scale from 0 to 4 (total score 0-12, with the higher score reflecting a higher level of function).
| Scores on a scale | Population: II BYM338 700 mg | Population: II Placebo |
|---|---|---|
| Population II: Short Physical Performance Battery (SPPB) Total Score at Week 49 | 8.6 ± 2.40 | 8.8 ± 1.55 |
The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is able to self-pace and rest as needed as they traverse back and forth along a marked walkway. A high 6MWT represent better physical condition.
| meters | Population I: BYM338 700 mg | Population I BYM338: 700 mg to Placebo | Population I: BYM338 210 mg | Population I BYM338: 210 mg to Placebo | Population I: BYM338 70 mg | Population I: BYM338 70 mg to Placebo | Population I: Placebo |
|---|---|---|---|---|---|---|---|
| Population I: 6-minute Walking Distance (6MWT) at Week 49 | 318.2 ± 159.55 | 354.1 ± 69.98 | 304.1 ± 63.05 | 361.5 ± 144.53 | 316.1 ± 97.87 | 273.4 ± 154.03 | 368.7 ± 108.37 |
The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is able to self-pace and rest as needed as they traverse back and forth along a marked walkway. A high 6MWT represent better physical condition.
| meters | Population: II BYM338 700 mg | Population: II Placebo |
|---|---|---|
| Population II: 6-minute Walking Distance (6MWT) at Week 49 | 321.2 ± 105.13 | 323.1 ± 96.47 |
Gait Speed was assessed as part of SPPB, over a 4 meter distance of a 6 meter course. Gait speed assesses a person's usual walking speed, which is defined as the speed a person normally walks from one place to another. Poor functional performance is measured by slow or declining gait speed.
| m/sec | Population I: BYM338 700 mg | Population I BYM338: 700 mg to Placebo | Population I: BYM338 210 mg | Population I BYM338: 210 mg to Placebo | Population I: BYM338 70 mg | Population I: BYM338 70 mg to Placebo | Population I: Placebo |
|---|---|---|---|---|---|---|---|
| Population I: Gait Speed at Week 49 | 0.8 ± 0.35 | 1.0 ± 0.18 | 0.9 ± 0.17 | 1.1 ± 0.24 | 0.9 ± 0.15 | 0.7 ± 0.35 | 0.8 ± 0.18 |
Gait Speed was assessed as part of SPPB, over a 4 meter distance of a 6 meter course. Gait speed assesses a person's usual walking speed, which is defined as the speed a person normally walks from one place to another. Poor functional performance is measured by slow or declining gait speed.
| m/sec | Population: II BYM338 700 mg | Population: II Placebo |
|---|---|---|
| Population II: Gait Speed at Week 49 | 0.9 ± 0.24 | 0.9 ± 0.17 |
ASMI is a core requirement for determining the presence of sarcopenia and is calculated as the sum of the appendicular lean mass (kg) of the two upper and two lower limbs quantified by DXA, divided by height (m2). Therefore, an increase in ASMI indicates an increase in the quantity of an individual's lean mass.
| kg/m^2 | Population I: BYM338 700 mg | Population I BYM338: 700 mg to Placebo | Population I: BYM338 210 mg | Population I BYM338: 210 mg to Placebo | Population I: BYM338 70 mg | Population I: BYM338 70 mg to Placebo | Population I: Placebo |
|---|---|---|---|---|---|---|---|
| Population I: Appendicular Skeletal Muscle Index (ASMI) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49 | 6.6 ± 7.22 | 6.0 ± 14.05 | 6.1 ± 8.08 | 5.8 ± 15.08 | 5.9 ± 14.19 | 5.2 ± 14.85 | 5.6 ± 15.21 |
ASMI is a core requirement for determining the presence of sarcopenia and is calculated as the sum of the appendicular lean mass (kg) of the two upper and two lower limbs quantified by DXA, divided by height (m2). Therefore, an increase in ASMI indicates an increase in the quantity of an individual's lean mass.
| kg/m^2 | Population: II BYM338 700 mg | Population: II Placebo |
|---|---|---|
| Population II: Appendicular Skeletal Muscle Index (ASMI) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49 | 5.6 ± 14.36 | 5.5 ± 12.46 |
LBM is defined as the Total soft tissue fat-free body mass. A high LBM represents better pharmacodynamic effect
| kg | Population I: BYM338 700 mg | Population I BYM338: 700 mg to Placebo | Population I: BYM338 210 mg | Population I BYM338: 210 mg to Placebo | Population I: BYM338 70 mg | Population I: BYM338 70 mg to Placebo | Population I: Placebo |
|---|---|---|---|---|---|---|---|
| Population I: Total Lean Body Mass (LBM) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49 | 41.4 ± 21.11 | 34.0 ± 17.76 | 35.5 ± 15.39 | 32.6 ± 25.23 | 34.9 ± 21.16 | 34.0 ± 18.47 | 32.6 ± 17.95 |
LBM is defined as the Total soft tissue fat-free body mass. A high LBM represents better pharmacodynamic effect
| kg | Population: II BYM338 700 mg | Population: II Placebo |
|---|---|---|
| Population II: Total Lean Body Mass (LBM) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49 | 34.9 ± 25.01 | 33.7 ± 20.40 |
Collected over Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum treatment duration of 24 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Population I BYM338 700 mg | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Population I BYM338 700 mg to Placebo | 0/5 (0%) | 1/5 (20%) | 4/5 (80%) |
| Population I BYM338 210 mg | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Population I BYM338 210 mg to Placebo | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Population I BYM338 70 mg | 0/7 (0%) | 0/7 (0%) | 5/7 (71.4%) |
| Population I BYM338 70 mg to Placebo | 0/7 (0%) | 2/7 (28.6%) | 3/7 (42.9%) |
| Population I Placebo | 0/15 (0%) | 2/15 (13.3%) | 11/15 (73.3%) |
| Population: II BYM338 700 mg | 0/69 (0%) | 0/69 (0%) | 0/69 (0%) |
| Population: II Placebo | 0/43 (0%) | 0/43 (0%) | 0/43 (0%) |
| Event | Population I BYM338 700 mg | Population I BYM338 700 mg to Placebo | Population I BYM338 210 mg | Population I BYM338 210 mg to Placebo | Population I BYM338 70 mg | Population I BYM338 70 mg to Placebo | Population I Placebo | Population: II BYM338 700 mg | Population: II Placebo |
|---|---|---|---|---|---|---|---|---|---|
| SeizureNervous system disorders | 0/5 | 1/5 | 0/5 | 0/4 | 0/7 | 0/7 | 0/15 | 0/69 | 0/43 |
| FallInjury, poisoning and procedural complications | 0/5 | 0/5 | 0/5 | 0/4 | 0/7 | 1/7 | 0/15 | 0/69 | 0/43 |
| Lumbar vertebral fractureInjury, poisoning and procedural complications | 0/5 | 0/5 | 0/5 | 0/4 | 0/7 | 1/7 | 0/15 | 0/69 | 0/43 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/5 | 0/5 | 0/5 | 0/4 | 0/7 | 1/7 | 0/15 | 0/69 | 0/43 |
| Gallbladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/5 | 0/5 | 0/5 | 0/4 | 0/7 | 1/7 | 0/15 | 0/69 | 0/43 |
| CataractEye disorders | 0/5 | 0/5 | 0/5 | 0/4 | 0/7 | 0/7 | 1/15 | 0/69 | 0/43 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/5 | 0/5 | 0/5 | 0/4 | 0/7 | 0/7 | 1/15 | 0/69 | 0/43 |
| Event | Population I BYM338 700 mg | Population I BYM338 700 mg to Placebo | Population I BYM338 210 mg | Population I BYM338 210 mg to Placebo | Population I BYM338 70 mg | Population I BYM338 70 mg to Placebo | Population I Placebo | Population: II BYM338 700 mg | Population: II Placebo |
|---|---|---|---|---|---|---|---|---|---|
| FallInjury, poisoning and procedural complications | 1/5 | 1/5 | 0/5 | 1/4 | 2/7 | 0/7 | 6/15 | 0/69 | 0/43 |
| Herpes zosterInfections and infestations | 0/5 | 0/5 | 0/5 | 0/4 | 2/7 | 0/7 | 1/15 | 0/69 | 0/43 |
| Back painMusculoskeletal and connective tissue disorders | 1/5 | 0/5 | 0/5 | 0/4 | 2/7 | 1/7 | 0/15 | 0/69 | 0/43 |
| Ventricular extrasystolesCardiac disorders | 0/5 | 0/5 | 0/5 | 1/4 | 0/7 | 0/7 | 0/15 | 0/69 | 0/43 |
| GastroenteritisInfections and infestations | 0/5 | 0/5 | 0/5 | 1/4 | 0/7 | 0/7 | 0/15 | 0/69 | 0/43 |
| Skin abrasionInjury, poisoning and procedural complications | 0/5 | 0/5 | 0/5 | 1/4 | 0/7 | 0/7 | 0/15 | 0/69 | 0/43 |
| Prostatic dysplasiaReproductive system and breast disorders | 0/5 | 0/5 | 0/5 | 1/4 | 0/7 | 0/7 | 0/15 | 0/69 | 0/43 |
| Dry eyeEye disorders | 0/5 | 0/5 | 1/5 | 0/4 | 0/7 | 0/7 | 0/15 | 0/69 | 0/43 |
| Chronic gastritisGastrointestinal disorders | 1/5 | 0/5 | 0/5 | 0/4 | 0/7 | 0/7 | 0/15 | 0/69 | 0/43 |
| Large intestine polypGastrointestinal disorders | 1/5 | 0/5 | 0/5 | 0/4 | 0/7 | 0/7 | 0/15 | 0/69 | 0/43 |
160 participants were enrolled into the study: 48 in Population I (patients enrolled prior to protocol amendment 1) and 112 in Population II (patients enrolled after protocol amendment 1)
| Age, Continuous(Years) | Population I: BYM338 700 mg | Population I BYM338: 700 mg to Placebo | Population I: BYM338 210 mg | Population I BYM338: 210 mg to Placebo | Population I: BYM338 70 mg | Population I: BYM338 70 mg to Placebo | Population I: Placebo | Population: II BYM338 700 mg | Population: II Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 80.0 ± 4.90 | 79.4 ± 7.27 | 79.0 ± 1.58 | 74.8 ± 2.63 | 77.6 ± 6.75 | 81.6 ± 4.58 | 79.9 ± 4.22 | — | — | 79.2 ± 4.91 |
| Age, Continuous(Years) | Population I: BYM338 700 mg | Population I BYM338: 700 mg to Placebo | Population I: BYM338 210 mg | Population I BYM338: 210 mg to Placebo | Population I: BYM338 70 mg | Population I: BYM338 70 mg to Placebo | Population I: Placebo | Population: II BYM338 700 mg | Population: II Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | — | — | — | — | — | — | — | 79.8 ± 5.05 | 78.2 ± 5.29 | 79.2 ± 5.18 |
| Sex: Female, Male(Participants) | Population I: BYM338 700 mg | Population I BYM338: 700 mg to Placebo | Population I: BYM338 210 mg | Population I BYM338: 210 mg to Placebo | Population I: BYM338 70 mg | Population I: BYM338 70 mg to Placebo | Population I: Placebo | Population: II BYM338 700 mg | Population: II Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 2 | 2 | 2 | 3 | 5 | 8 | 0 | 0 | 23 |
| Male | 4 | 3 | 3 | 2 | 4 | 2 | 7 | 0 | 0 | 25 |
| Sex: Female, Male(Participants) | Population I: BYM338 700 mg | Population I BYM338: 700 mg to Placebo | Population I: BYM338 210 mg | Population I BYM338: 210 mg to Placebo | Population I: BYM338 70 mg | Population I: BYM338 70 mg to Placebo | Population I: Placebo | Population: II BYM338 700 mg | Population: II Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40 | 29 | 69 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 29 | 14 | 43 |
| Race/Ethnicity, Customized(Participants) | Population I: BYM338 700 mg | Population I BYM338: 700 mg to Placebo | Population I: BYM338 210 mg | Population I BYM338: 210 mg to Placebo | Population I: BYM338 70 mg | Population I: BYM338 70 mg to Placebo | Population I: Placebo | Population: II BYM338 700 mg | Population: II Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Asian | 1 | 0 | 0 | 1 | 2 | 2 | 6 | — | — | 12 |
| Black | 0 | 0 | 0 | 0 | 1 | 1 | 1 | — | — | 3 |
| Caucasian | 4 | 5 | 5 | 3 | 4 | 4 | 8 | — | — | 33 |
| Race/Ethnicity, Customized(Participants) | Population I: BYM338 700 mg | Population I BYM338: 700 mg to Placebo | Population I: BYM338 210 mg | Population I BYM338: 210 mg to Placebo | Population I: BYM338 70 mg | Population I: BYM338 70 mg to Placebo | Population I: Placebo | Population: II BYM338 700 mg | Population: II Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Asian | — | — | — | — | — | — | — | 11 | 3 | 14 |
| Caucasian | — | — | — | — | — | — | — | 56 | 40 | 96 |
| Native American | — | — | — | — | — | — | — | 1 | 0 | 1 |
| Pacific Islander | — | — | — | — | — | — | — | 1 | 0 | 1 |
| Population I: Short Physical Performance Battery (SPPB) total score at Week 25(Scores on a scale) | Population I: BYM338 700 mg | Population I BYM338: 700 mg to Placebo | Population I: BYM338 210 mg | Population I BYM338: 210 mg to Placebo | Population I: BYM338 70 mg | Population I: BYM338 70 mg to Placebo | Population I: Placebo | Population: II BYM338 700 mg | Population: II Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 8.8 ± 2.17 | 10.4 ± 1.34 | 8.6 ± 1.67 | 8.5 ± 1.91 | 8.9 ± 2.04 | 8.0 ± 3.27 | 9.1 ± 1.58 | — | — | 8.9 ± 2.01 |
| Population II: Short Physical Performance Battery (SPPB) total score at Week 25(Scores on a scale) | Population I: BYM338 700 mg | Population I BYM338: 700 mg to Placebo | Population I: BYM338 210 mg | Population I BYM338: 210 mg to Placebo | Population I: BYM338 70 mg | Population I: BYM338 70 mg to Placebo | Population I: Placebo | Population: II BYM338 700 mg | Population: II Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | — | — | — | — | — | — | — | 8.5 ± 2.17 | 8.2 ± 2.25 | 8.4 ± 2.20 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jul 2015 to primary completion in Dec 2018, 40 months.
Results were first posted in Dec 2019, 1 year after primary completion.
Of 20 phase 2 interventional studies under Sarcopenia, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 40 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimagrumab